Smith & Nephew plc Overview
Smith & Nephew plc (SNN) has a ROE of 21.77%, below the Healthcare sector average of 22.76%.
Get informed when a big investor buys or sells
+ Follow21.77%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Smith & Nephew plc's return on equity stands at 21.77%. That is below the Healthcare sector average of 22.76%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Smith & Nephew plc sits lower the Healthcare benchmark (22.76%) with a ROE of 21.77%. That is roughly 4.4% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 21.77% for Smith & Nephew plc means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Smith & Nephew plc's ROE evolved across reporting periods, while the comparison chart places SNN next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, ROE is commonly used to spot outliers. Smith & Nephew plc's reading of 21.77% (sector avg 22.76%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
